Johnson & Johnson
JNJ- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000200406
In the last 90 days, Johnson & Johnson insiders filed 0 open-market purchases and 3 sales; 4,720 institutions reported holding it in 13F filings for Q2 2026, worth $457.0B in total; 5 superinvestors hold it, including Markel Group and Fairfax Financial.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 22, 2026, 1:07 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Jan 1, 2023 | Jan 2, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 21, 2026 | Jan 22, 2025 | Jan 23, 2024 | Jan 24, 2023 | Jan 25, 2022 |
| Revenue | $94.2B | $88.8B | $85.2B | $94.9B | $93.8B |
| Cost of revenue | $30.3B | $27.5B | $26.6B | $31.1B | $29.9B |
| Gross profit | $63.9B | $61.4B | $58.6B | $63.9B | $63.9B |
| Research and development | $109.0M | $1.84B | $483.0M | $14.6B | $14.7B |
| Selling, general and administrative | $23.7B | $22.9B | $21.5B | $24.8B | $24.7B |
| Interest expense | – | – | $772.0M | $276.0M | $183.0M |
| Income tax | $5.78B | $2.62B | $1.74B | $3.78B | $1.90B |
| Net income | $26.8B | $14.1B | $35.2B | $17.9B | $20.9B |
| EPS, basic | $11.13 | $5.84 | $13.88 | $6.83 | $7.93 |
| EPS, diluted | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 |
| Weighted shares, basic | 2.41B | 2.41B | 2.53B | 2.63B | 2.63B |
| Weighted shares, diluted | 2.43B | 2.43B | 2.56B | 2.66B | 2.67B |
| Margins and growth | |||||
| Gross margin | 67.9% | 69.1% | 68.8% | 67.3% | 68.2% |
| Net margin | 28.5% | 15.8% | 41.3% | 18.9% | 22.3% |
| Revenue growth, year over year | +6.0% | +4.3% | −10.3% | +1.2% | +13.6% |
| Net income growth, year over year | +90.6% | −60.0% | +95.9% | −14.1% | +41.9% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Jan 1, 2023 | Jan 2, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 21, 2026 | Jan 22, 2025 | Jan 23, 2024 | Jan 24, 2023 | Jan 25, 2022 |
| Cash and equivalents | $19.7B | $24.1B | $21.9B | $14.1B | $14.5B |
| Short-term investments | $393.0M | $417.0M | $1.07B | $9.39B | $17.1B |
| Accounts receivable | $17.2B | $14.8B | $14.9B | $16.2B | $15.3B |
| Inventory | $14.2B | $12.4B | $11.2B | $12.5B | $10.4B |
| Total current assets | $55.6B | $55.9B | $53.5B | $55.3B | $61.0B |
| Property, plant and equipment | $23.2B | $20.5B | $19.9B | $19.8B | $19.0B |
| Goodwill | $48.8B | $44.2B | $36.6B | $45.2B | $35.2B |
| Intangible assets | $50.4B | $37.6B | $34.2B | $48.3B | $46.4B |
| Total assets | $199.2B | $180.1B | $167.6B | $187.4B | $182.0B |
| Accounts payable | $12.0B | $10.3B | $9.63B | $11.7B | $11.1B |
| Short-term debt | $8.49B | $5.98B | $3.45B | $12.8B | $3.77B |
| Total current liabilities | $54.1B | $50.3B | $46.3B | $55.8B | $45.2B |
| Long-term debt | $39.4B | $30.7B | $25.9B | $26.9B | $30.0B |
| Total liabilities | $117.7B | $108.6B | $98.8B | $110.6B | $108.0B |
| Shareholders' equity | $81.5B | $71.5B | $68.8B | $76.8B | $74.0B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Jan 1, 2023 | Jan 2, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 21, 2026 | Jan 22, 2025 | Jan 23, 2024 | Jan 24, 2023 | Jan 25, 2022 |
| Operating cash flow | $24.5B | $24.3B | $22.8B | $21.2B | $23.4B |
| Capital expenditures | $4.83B | $4.42B | $4.54B | $4.01B | $3.65B |
| Free cash flow | $19.7B | $19.8B | $18.2B | $17.2B | $19.8B |
| Depreciation and amortization | $7.50B | $7.34B | $7.49B | $6.97B | $7.39B |
| Stock-based compensation | $1.35B | $1.18B | $1.16B | $1.14B | $1.14B |
| Share buybacks | $5.95B | $2.43B | $5.05B | $6.04B | $3.46B |
| Investing cash flow | -$23.6B | -$18.6B | $878.0M | -$12.4B | -$8.68B |
| Financing cash flow | -$5.54B | -$3.13B | -$15.8B | -$8.87B | -$14.0B |
| Net change in cash | -$4.40B | $2.25B | $7.73B | -$360.0M | $502.0M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 1.4% | 1.3% | 1.4% | 1.2% | 1.2% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.